Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Conference Call February 22, 2024 8:00 AM ET
Company Participants
Ian Karp - SVP, IR and Corporate Communications
John Leonard - President and CEO
David Lebwohl - EVP and CMO
Laura Sepp-Lorenzino - EVP and CSO
Glenn Goddard - EVP and Chief Financial Officer
Eliana Clark - EVP and CTO
Conference Call Participants
Maury Raycroft - Jefferies
Unidentified Analyst - RBC
Greg Harrison - Bank of America
Unidentified Analyst - Barclays
Troy Langford - TD Cowen
Kostas Biliouris - BMO Capital Markets
Unidentified Analyst - Stifel
Unidentified Analyst - Truist Securities
Brian Cheng - J.P. Morgan
Unidentified Analyst - Goldman Sachs
Unidentified Analyst - Guggenheim Partners
William Pickering - Bernstein
Rick Bienkowski - Cantor Fitzgerald
Yanan Zhu - Wells Fargo Securities
Unidentified Analyst - Raymond James
Jay Olson - Oppenheimer
Silvan Tuerkcan - JMP Securities
David Lebowitz - Citigroup
Jack Allen - Robert W. Baird
Operator
Good morning and welcome to the Intellia Therapeutics' Fourth Quarter and Full Year 2023 Financial Results Conference Call. My name is Drew and I will be your conference operator today. Following formal remarks, we will open the call up for a question-and-answer session. This conference is being recorded at the Company's request and will be available on the Company's website following the end of the call. As a reminder, all participants are currently in a listen-only mode. [Operator Instructions]. I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.
Ian Karp
Thank you, operator and good morning, everyone. Welcome to Intellia Therapeutics fourth quarter and full year 2023 earnings call. Earlier this morning, Intellia issued a press release outlining the Company's progress this quarter, as well as topics for discussion on today's call. This release can be found on the Investors & Media section of Intellia's website at intelliatx.com. This call is being broadcast live and a replay will be archived on the Company's website.
At this time, I would like to take a minute to remind listeners that during the call, Intellia management may make certain forward-looking statements and ask that you refer to our SEC filings available at sec.gov for a discussion of potential risks and uncertainties. All information presented on this call is current as of today, and Intellia undertakes no duty to update this information unless required by law.
Joining me from Intellia are John Leonard, Chief Executive Officer; David Lebwohl, Chief Medical Officer; and Laura Sepp-Lorenzino, Chief Scientific Officer; and Glenn Goddard, Chief Financial Officer. John will begin with an overview of recent business highlights. David will provide an update on our clinical pipeline progress, Laura will review our R&D updates, and Glenn will review our financials before we open up the call for questions. With that, I'll now turn the call over to John, our Chief Executive Officer.